Miniatura

Fitxers

894495.pdf (494.65 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2025-10-01

Llicència de publicació

cc-by-nc-nd (c) Roldán, Fiorella L. et al., 2025
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/228876

Bladder EpiCheck clinical utility to predict BCG response in non-muscle-invasive bladder cancer

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1111/bju.16697

Resum

Objective: To evaluate the performance of Bladder Epicheck® (BE; Nucleix Ltd., Rehovot, Israel) in predicting tumour recurrence and bacillus Calmette-Guérin (BCG) failure during the first year after induction treatment. Patients and methods: Prospective study including 65 patients with non-muscle-invasive bladder cancer treated with BCG between 2018 and 2021. Urine samples analysed with BE were collected before and after BCG induction. Logistic binary regression was used to assess the association between clinical and pathological variables and BE results with tumour recurrence and BCG failure during the first year after induction treatment. Results: During follow-up, 16 (24.6%) patients experienced a bladder cancer event, 11 (68.8%) of which were BCG failure (high-grade recurrence) and five (31.2%) were low-grade recurrences. The median (range) time to overall recurrence was 7.3 (3.8-17.4) months. A significant association was found between the risk of tumour recurrence/BCG failure and post-BCG cystoscopy (odds ratio [OR] 10.0; P < 0.001 and OR 13.1; P < 0.001, respectively), post-BCG BE result (OR 16.9; P < 0.001 and OR 33.1; P < 0.001, respectively) and pre/post-BCG EpiScore value variation (OR 14.4; P = 0.001 and OR 7.1; P = 0.018, respectively). A nomogram including these three variables outperformed the Club Urológico Español de Tratamiento Oncológico (CUETO) risk tables to predict any bladder cancer event after BCG induction (area under the curve 95.1% vs 67.1%). Result validation in a larger and independent series is needed. Conclusions: The BE post-BCG status and variations in EpiScore values can help us identify patients at higher risk of any bladder cancer event and BCG failure promptly. These data can have an impact on disease management.

Matèries

Marcadors bioquímics, Càncer de bufeta, Orina

Matèries (anglès)

Biochemical markers, Bladder cancer, Urine

Citació

Col·leccions

Articles publicats en revistes (Biomedicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citació

ROLDÁN, Fiorella l., INGELMO-TORRES, Mercedes, MERCADER BARRULL, Clàudia, FIGUERAS TORRAS, Marcel, PADULLÉS, Bernat, DURÁN GONZÁLEZ, María angeles, CARRASCO JORDAN, Josep lluís, RIBAL, María josé, FRANCO DE CASTRO, Agustín, IZQUIERDO REYES, Laura, ALCARAZ ASENSIO, Antonio, MENGUAL BRICHS, Lourdes. Bladder EpiCheck clinical utility to predict BCG response in non-muscle-invasive bladder cancer. _BJU International_. 2025. Vol. 136, núm. 4, pàgs. 682-689. [consulta: 1 de maig de 2026]. ISSN: 1464-4096. [Disponible a: https://hdl.handle.net/2445/228876]

Exportar metadades

JSON - METS

Compartir registre